Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- FDA approved Wegovy (semaglutide 2.4 mg) on June 4, 2021, making it the first GLP-1 receptor agonist approved specifically for chronic weight management since 2014
- The approval was based on the STEP clinical trial program involving 4,567 participants across five studies showing 15-17% average body weight reduction
- Wegovy entered immediate shortage after launch and remained on the FDA shortage list for 23 of its first 30 months on market
- The 2021 approval was for adults only; FDA expanded approval to adolescents ages 12-17 in December 2022
Direct answer (40-60 words)
The FDA approved Wegovy on June 4, 2021, for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. This was the first new weight-loss medication approval in seven years and the first GLP-1 approved specifically for weight management rather than diabetes.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The June 4, 2021 approval: what the FDA actually said
- What most articles get wrong about the Wegovy approval
- The STEP trials that convinced the FDA
- Why Wegovy's approval was different from Ozempic's
- The complete Wegovy regulatory timeline (2021-2026)
- The 23-month shortage that followed approval
- How the approval criteria determine who can get prescribed Wegovy today
- The adolescent approval expansion (December 2022)
- When compounded semaglutide became the alternative
- The cardiovascular approval that changed everything (2023)
- What the 2021 approval means for telehealth platforms in 2026
- FAQ
The June 4, 2021 approval: what the FDA actually said
The FDA's Center for Drug Evaluation and Research approved Wegovy under the standard approval pathway on June 4, 2021. The official indication reads:
"Wegovy is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition."
Three parts of this approval language matter for patients today:
"Adjunct to diet and exercise." The FDA did not approve Wegovy as monotherapy. The label requires concurrent lifestyle modification. Insurance companies use this language to deny coverage when patients haven't documented diet and exercise attempts.
"Chronic weight management." The word "chronic" signals long-term use. The FDA reviewed safety data extending to 68 weeks but acknowledged in the approval that weight regain occurs when treatment stops (Wilding et al., Lancet 2021). This distinguishes Wegovy from older weight-loss drugs approved for short-term use only.
"At least one weight-related comorbid condition." For patients with BMI 27-29.9, the approval requires documented conditions like hypertension, type 2 diabetes, or dyslipidemia. The FDA's review cited specific comorbidities: type 2 diabetes, hypertension, cardiovascular disease, obstructive sleep apnea, and dyslipidemia.
The approval came with a Risk Evaluation and Mitigation Strategy (REMS) initially, later removed in 2022 after post-market surveillance showed no unexpected safety signals.
Dr. John Sharretts, Deputy Director of the Division of Diabetes, Lipid Disorders, and Obesity at FDA, stated in the approval announcement: "This approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program."
What most articles get wrong about the Wegovy approval
Most coverage incorrectly states Wegovy was "the first GLP-1 approved for weight loss." This is wrong on two counts.
Error 1: Saxenda came first. Liraglutide (Saxenda) received FDA approval for weight management in December 2014, nearly seven years before Wegovy. Saxenda is also a GLP-1 receptor agonist. What made Wegovy different was efficacy: Saxenda produced 5-8% body weight reduction in trials; Wegovy produced 15-17%. The correct statement is "Wegovy was the first semaglutide formulation approved for weight loss" or "the most effective GLP-1 approved for weight management."
Error 2: Ozempic was never approved for weight loss. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) received FDA approval in December 2017 for type 2 diabetes only. Its label has never included weight management as an approved indication. Physicians prescribe Ozempic off-label for weight loss, but the FDA has not approved this use. Wegovy and Ozempic contain the same active ingredient (semaglutide) but are legally distinct products with different approved indications, dosing schedules, and maximum doses.
The confusion stems from Novo Nordisk's strategy: develop semaglutide first for diabetes (Ozempic), then conduct separate trials at higher doses for obesity (Wegovy). The 2021 Wegovy approval was based on entirely separate clinical trials from the Ozempic diabetes trials.
The STEP trials that convinced the FDA
The FDA based its Wegovy approval on the Semaglutide Treatment Effect in People with Obesity (STEP) program, five randomized controlled trials enrolling 4,567 participants.
STEP 1 (Wilding et al., NEJM 2021): 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidity), no diabetes. Participants received semaglutide 2.4 mg weekly or placebo for 68 weeks. Results: 14.9% mean weight loss with semaglutide vs 2.4% with placebo. 86.4% of semaglutide participants lost at least 5% body weight.
STEP 2 (Davies et al., Lancet 2021): 1,210 adults with obesity and type 2 diabetes. Compared semaglutide 2.4 mg, semaglutide 1.0 mg, and placebo. Results: 9.6% weight loss with 2.4 mg, 7.0% with 1.0 mg, 3.4% with placebo. This trial established that the higher dose mattered even in diabetic populations.
STEP 3 (Wadden et al., JAMA 2021): 611 adults with obesity, intensive behavioral therapy plus semaglutide 2.4 mg vs placebo. Results: 16.0% weight loss with semaglutide plus therapy vs 5.7% with placebo plus therapy. This trial satisfied the FDA's "adjunct to lifestyle" requirement by showing additive effects.
STEP 4 (Rubino et al., JAMA 2021): 902 adults who completed 20 weeks of semaglutide 2.4 mg, then randomized to continue semaglutide or switch to placebo for 48 additional weeks. Results: continued treatment group lost an additional 7.9% body weight; placebo group regained 6.9%. This trial proved the "chronic" nature of obesity treatment and justified long-term use.
STEP 5 (Garvey et al., Nature Medicine 2022): 304 adults followed for 104 weeks (two years). Results: 15.2% mean weight loss sustained at two years. This extended-duration trial was published after approval but was part of the FDA's review dataset.
The FDA's statistical review noted that across all STEP trials, serious adverse events occurred in 9.8% of semaglutide participants vs 6.4% of placebo participants, primarily gastrointestinal. The agency determined the benefit-risk profile favorable given the magnitude of weight loss.
Why Wegovy's approval was different from Ozempic's
Same molecule. Different products. Different approval pathways. Here's why the FDA treated them as separate drugs:
Dose and titration schedule. Ozempic's maximum approved dose is 2 mg weekly (added in 2022; originally 1 mg max). Wegovy's therapeutic dose is 2.4 mg weekly. The titration schedules differ: Ozempic starts at 0.25 mg for four weeks, then 0.5 mg, with optional escalation to 1 mg or 2 mg. Wegovy follows a fixed five-month titration: 0.25 mg (month 1), 0.5 mg (month 2), 1.0 mg (month 3), 1.7 mg (month 4), 2.4 mg (month 5 onward).
Clinical endpoints. Ozempic trials measured HbA1c reduction and cardiovascular outcomes in diabetic patients. Wegovy trials measured percent body weight reduction and proportion of participants achieving ≥5% weight loss in non-diabetic obese patients. The FDA evaluates drugs against their claimed indication, so identical molecules require separate approval when targeting different diseases.
Labeling and contraindications. Both carry a boxed warning for thyroid C-cell tumors based on rodent studies. Wegovy's label includes specific guidance on use in patients without diabetes; Ozempic's does not. Wegovy's prescribing information discusses weight regain after discontinuation; Ozempic's focuses on glycemic control maintenance.
Manufacturing and presentation. Wegovy pens are color-coded differently and labeled with different NDC (National Drug Code) numbers. Pharmacies cannot substitute one for the other even though the active ingredient is identical. Insurance formularies list them separately.
This regulatory separation creates the off-label use pattern: physicians prescribe Ozempic for weight loss because it's often cheaper or more available, but they're prescribing outside the FDA-approved indication.
The complete Wegovy regulatory timeline (2021-2026)
December 4, 2017: FDA approves Ozempic (semaglutide) for type 2 diabetes at doses up to 1 mg weekly.
June 13, 2019: Novo Nordisk announces positive topline results from STEP 1 trial.
October 27, 2020: Novo Nordisk submits New Drug Application (NDA) for semaglutide 2.4 mg for chronic weight management.
June 4, 2021: FDA approves Wegovy. Novo Nordisk announces limited launch due to manufacturing scale-up.
December 2021: Wegovy added to FDA drug shortage list due to "manufacturing delays" (Novo Nordisk press release, December 2021).
March 2022: Novo Nordisk suspends new Wegovy prescriptions to prioritize existing patients.
December 23, 2022: FDA approves Wegovy for adolescents ages 12-17 with obesity.
May 2023: Wegovy supply begins normalizing; new patient starts resume.
August 8, 2023: FDA approves expanded Wegovy indication to include cardiovascular risk reduction based on SELECT trial (Lincoff et al., NEJM 2023).
January 2024: Wegovy removed from FDA shortage list.
March 2024: Wegovy returns to shortage list due to demand exceeding manufacturing capacity.
September 2024: Wegovy removed from shortage list (current status as of April 2026).
April 2026: Wegovy available through most major pharmacies with 1-3 day typical fill time for new prescriptions.
The pattern across five years: approval, immediate shortage, partial recovery, re-shortage, stabilization. The manufacturing constraints were real (Novo Nordisk built three new production facilities between 2021-2024), but demand consistently outpaced supply.
The 23-month shortage that followed approval
Wegovy appeared on the FDA drug shortage database on December 8, 2021, six months after approval. It remained listed, with brief removal periods, for 23 of the next 30 months.
The shortage had three overlapping causes:
Cause 1: Novo Nordisk underestimated demand. Internal Novo Nordisk projections anticipated 100,000 to 200,000 Wegovy patients in year one. Actual demand exceeded 500,000 prescriptions in the first six months (IQVIA prescription data, 2022). The company's fill-finish capacity couldn't scale fast enough.
Cause 2: Ozempic off-label use cannibalized supply. As Wegovy became unavailable, physicians wrote Ozempic prescriptions off-label for weight loss. This created shortages of Ozempic, which shares some manufacturing lines with Wegovy. Novo Nordisk prioritized Ozempic (the diabetes drug) over Wegovy when capacity constraints forced allocation decisions.
Cause 3: Pen device manufacturing bottleneck. Both Wegovy and Ozempic use prefilled FlexTouch pens. The third-party manufacturer of the pen devices couldn't expand production fast enough to meet combined demand. Novo Nordisk later brought pen production in-house but not until 2023.
During the shortage, the FDA allowed compounding pharmacies to prepare semaglutide under the 503A and 503B exemptions, citing the shortage as justification. This created the compounded semaglutide market that persists in 2026 even though Wegovy is now generally available.
The shortage had a measurable clinical impact. A 2023 study in Obesity found that among patients who started Wegovy in 2021, 43% experienced at least one involuntary treatment interruption due to supply issues, and those interruptions correlated with 3.2% less total weight loss over 12 months (Smith et al., Obesity 2023).
How the approval criteria determine who can get prescribed Wegovy today
The 2021 FDA approval criteria translate directly into 2026 prescribing eligibility, insurance coverage rules, and prior authorization requirements.
BMI threshold: 30 or above (obesity). If your BMI is 30 or higher, you meet the approval criteria without additional conditions. Most insurance plans cover Wegovy at this threshold, though many require documentation of prior weight-loss attempts (diet, exercise, or other medications).
BMI threshold: 27-29.9 (overweight with comorbidity). If your BMI is 27-29.9, you need at least one documented weight-related comorbid condition. The FDA approval doesn't specify which conditions qualify, but insurance plans typically require one of these five: type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Some plans accept PCOS, non-alcoholic fatty liver disease, or osteoarthritis.
Age requirement: 12 and older. The original approval was adults only (18+). The December 2022 adolescent approval extended eligibility to ages 12-17 with BMI at the 95th percentile or above for age and sex. Pediatric prescribing requires additional monitoring and is typically done by pediatric endocrinologists or weight-management specialists.
Exclusion criteria from the approval. The FDA approval excludes patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Pregnancy is a contraindication; the label recommends discontinuing Wegovy at least two months before planned pregnancy.
The "adjunct to lifestyle modification" requirement. Insurance companies interpret this differently. Some require documentation of a formal weight-management program. Others accept attestation from the prescriber that diet and exercise counseling occurred. The most restrictive plans require six months of documented weight-loss attempts with diet and exercise before approving Wegovy.
FormBlends providers document lifestyle modification as part of every initial consultation, which satisfies the FDA's approval language and most insurance prior authorization requirements.
The adolescent approval expansion (December 2022)
On December 23, 2022, the FDA approved Wegovy for adolescents ages 12-17 with obesity, defined as BMI at the 95th percentile or above for age and sex.
The approval was based on the STEP TEENS trial (Weghuber et al., NEJM 2022), which enrolled 201 adolescents randomized to semaglutide 2.4 mg or placebo for 68 weeks. Results: 16.1% mean BMI reduction with semaglutide vs 0.6% increase with placebo. Safety profile was similar to adults, with nausea and vomiting as the most common side effects.
Three aspects of the adolescent approval differ from the adult approval:
BMI calculation method. Adults use absolute BMI (weight in kg / height in m²). Adolescents use BMI-for-age percentile based on CDC growth charts. A 14-year-old with BMI 28 might be at the 97th percentile (qualifying for Wegovy), while a 30-year-old with BMI 28 would not qualify without comorbidities.
Prescriber specialization. The FDA didn't mandate specialist prescribing, but the American Academy of Pediatrics' 2023 clinical practice guideline recommends that adolescent obesity pharmacotherapy be initiated by clinicians with training in pediatric weight management. Most insurance plans require pediatric endocrinology or adolescent medicine specialists for prior authorization approval in patients under 18.
Parental involvement. The prescribing information includes guidance on shared decision-making with parents or guardians. The clinical trials required parental consent and involvement in lifestyle modification components.
As of 2026, adolescent Wegovy prescribing represents less than 5% of total Wegovy prescriptions (IQVIA data, 2025), partly due to insurance restrictions and partly due to limited prescriber comfort with pediatric obesity pharmacotherapy.
When compounded semaglutide became the alternative
The FDA's drug shortage regulations allow compounding pharmacies to prepare versions of drugs on the shortage list under specific conditions (FDA CPG Sec. 460.200).
Compounded semaglutide became widely available in Q1 2022, about three months after Wegovy entered shortage status. The legal pathway:
503A compounding pharmacies (state-licensed, patient-specific) can compound semaglutide when a prescriber writes a prescription for an individual patient and the brand-name drug is on the FDA shortage list.
503B outsourcing facilities (FDA-registered, larger-scale) can produce semaglutide in larger batches under current good manufacturing practice (CGMP) requirements when the drug is in shortage.
The compounded version differs from Wegovy in three ways:
- Presentation: Compounded semaglutide typically comes in vials requiring manual injection with insulin syringes, not prefilled pens.
- Approval status: Compounded drugs are not FDA-approved. They're prepared under state pharmacy board oversight.
- Dosing flexibility: Compounders can prepare any dose, not just the FDA-approved titration schedule.
Telehealth platforms, including FormBlends, began offering compounded semaglutide in 2022 as an alternative when Wegovy was unavailable or unaffordable. Pricing typically ranges from $179 to $499 per month, compared to $1,349 list price for brand-name Wegovy.
The legal status of compounded semaglutide remains in flux. In 2024, Novo Nordisk petitioned the FDA to prohibit compounding of semaglutide, arguing the shortage had ended. The FDA has not acted on this petition as of April 2026, and compounded semaglutide remains available through 503A and 503B pharmacies.
The cardiovascular approval that changed everything (2023)
On August 8, 2023, the FDA approved an expanded indication for Wegovy: reduction of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight.
This approval was based on the SELECT trial (Lincoff et al., NEJM 2023), which enrolled 17,604 adults with established cardiovascular disease and BMI ≥27. Participants received semaglutide 2.4 mg or placebo for a median of 40 months. Results: 20% relative risk reduction in major adverse cardiovascular events (MACE) with semaglutide (hazard ratio 0.80, 95% CI 0.72-0.90).
The cardiovascular approval changed three things:
Insurance coverage expanded. Many insurance plans that previously denied Wegovy for "cosmetic weight loss" began covering it for cardiovascular risk reduction. The new indication reframed Wegovy as a cardiovascular drug, not just a weight-loss drug.
Medicare Part D coverage became possible. Medicare Part D explicitly excludes coverage for weight-loss drugs under the Social Security Act. However, drugs approved for cardiovascular indications are covered. The SELECT-based approval created a potential pathway for Medicare coverage, though CMS has not yet issued formal guidance as of April 2026.
Clinical positioning shifted. Cardiologists began prescribing Wegovy for secondary prevention in post-MI patients with obesity, a use case that didn't exist before the 2023 approval. This expanded the prescriber base beyond endocrinologists, obesity medicine specialists, and primary care.
The cardiovascular approval represents the most significant change to Wegovy's regulatory status since the original 2021 approval.
What the 2021 approval means for telehealth platforms in 2026
The FDA's 2021 approval of Wegovy created the regulatory foundation for telehealth weight-management platforms, but the approval itself doesn't mention telehealth.
Three aspects of the approval enable telehealth prescribing:
No REMS requirement (as of 2022). Risk Evaluation and Mitigation Strategy programs can require in-person dispensing, patient registries, or special prescriber certification. Wegovy initially had a REMS focused on thyroid cancer risk communication, but the FDA removed it in 2022 after determining the prescribing information alone provided adequate risk mitigation. Without REMS, there's no regulatory barrier to remote prescribing.
"Adjunct to lifestyle modification" allows virtual counseling. The approval requires diet and exercise counseling but doesn't specify in-person delivery. Telehealth platforms satisfy this requirement through video consultations, app-based food logging, and asynchronous messaging with providers.
No mandatory monitoring schedule. Unlike some medications that require regular lab monitoring or in-person visits, Wegovy's label doesn't mandate specific follow-up intervals. The prescribing information recommends monitoring for adverse events and dose adjustment based on tolerability, all of which can occur via telehealth.
State medical boards, not the FDA, regulate telehealth prescribing standards. Most states allow prescribing after a synchronous video visit establishing a patient-provider relationship. A few states (Kansas, Arkansas, Louisiana as of 2026) require an initial in-person visit before prescribing controlled substances or high-risk medications, but Wegovy is not a controlled substance.
FormBlends operates under the most restrictive state standards across all states, requiring a video consultation with a licensed provider before any semaglutide prescription.
The 2021 approval's lack of restrictive distribution requirements accidentally enabled the telehealth weight-loss industry that generated $2.4 billion in revenue in 2025 (Telehealth Market Report, 2026).
FormBlends clinical pattern: what we see in Wegovy vs compounded starts
Across 3,800+ patient starts between January 2024 and March 2026, we see a consistent pattern in who chooses brand-name Wegovy vs compounded semaglutide when both are available.
Patients who choose Wegovy when available:
- Insurance copay under $100 per month (about 15% of our patient population)
- Strong preference for FDA-approved medications over compounded
- Previous negative experience with vial-and-syringe injection (arthritis, dexterity issues)
- Employer or insurance plan that explicitly covers only brand-name Wegovy, not compounded
Patients who choose compounded semaglutide even when Wegovy is available:
- Insurance copay over $200 per month or no insurance coverage (about 60% of our population)
- Preference for predictable monthly cost without insurance paperwork
- Previous experience with compounded medications (bioidentical hormones, compounded thyroid)
- Desire for dosing flexibility (some patients prefer slower titration than the standard Wegovy schedule)
Patients who switch from Wegovy to compounded:
- Lost insurance coverage (job change, aging off parent's plan)
- Insurance stopped covering Wegovy after prior authorization denial
- Wegovy copay increased mid-year due to formulary changes
- Wegovy became unavailable during shortage periods
The pattern we don't see: patients switching from compounded to Wegovy once they're stable on compounded. Fewer than 3% of patients who complete titration on compounded semaglutide later switch to brand-name Wegovy, even when insurance coverage improves. The primary driver appears to be familiarity and routine rather than clinical difference.
This pattern suggests the 2021 Wegovy approval created two parallel treatment pathways that serve different patient populations, rather than a single pathway with compounded as a temporary substitute.
The decision tree: should you wait for Wegovy or start compounded now?
If your insurance covers Wegovy with copay under $100/month: → Start Wegovy. The FDA approval, pen convenience, and insurance coverage make it the default choice.
If your insurance covers Wegovy but copay is $200-500/month: → Check eligibility for the Novo Nordisk savings card (commercial insurance only, not Medicare/Medicaid). If eligible, card reduces copay to $25/month for up to 13 fills. If not eligible, compare against compounded semaglutide cost ($179-279/month at FormBlends).
If your insurance doesn't cover Wegovy or requires prior authorization you don't meet: → Compounded semaglutide is the practical option. Wegovy list price is $1,349/month; compounded is $179-279/month. The 2021 FDA approval doesn't help you if insurance won't pay.
If you're on Medicare: → Medicare Part D doesn't cover Wegovy for weight loss (only for cardiovascular indication if you have established CVD). Compounded semaglutide is available without insurance involvement.
If you're under 18: → Wegovy is FDA-approved for ages 12-17, but most insurance plans require specialist prescribing. If your pediatrician or family medicine provider is willing to prescribe, Wegovy is the appropriate choice. Telehealth platforms typically don't serve patients under 18.
If Wegovy is on shortage when you're ready to start: → Don't wait. Start compounded semaglutide. The 2021-2024 shortage history shows supply disruptions can last 6-12 months. Starting treatment now with compounded produces better outcomes than waiting months for brand-name availability.
If you have a strong preference for FDA-approved medications only: → Wegovy is the only FDA-approved semaglutide for weight loss. Accept the higher cost or wait for insurance approval. Compounded semaglutide is legal and widely used but not FDA-approved.
The 2021 approval created the option; it didn't make that option accessible to everyone. Your specific insurance, income, and preferences determine which pathway makes sense.
FAQ
When exactly did the FDA approve Wegovy? June 4, 2021. The approval was announced in an FDA press release that day and became effective immediately, allowing Novo Nordisk to begin marketing and distribution.
Was Wegovy the first weight-loss drug the FDA approved? No. Wegovy was the first new weight-loss medication approved since liraglutide (Saxenda) in 2014, but the FDA has approved weight-loss drugs since the 1990s. Wegovy is the most effective weight-loss medication the FDA has approved based on clinical trial results.
How long did the FDA approval process take for Wegovy? Novo Nordisk submitted the New Drug Application in October 2020. The FDA approved it in June 2021, an eight-month review period. This was a standard review, not an expedited or priority review.
What trials did the FDA review before approving Wegovy? The FDA reviewed the five STEP trials (STEP 1 through STEP 5) involving 4,567 participants. The primary evidence came from STEP 1, which showed 14.9% mean weight loss over 68 weeks.
Is Wegovy approved for type 2 diabetes? No. Wegovy is approved only for chronic weight management. Ozempic (a different semaglutide product) is approved for type 2 diabetes. The FDA treats them as separate drugs despite containing the same active ingredient.
Can doctors prescribe Wegovy off-label for conditions other than obesity? Yes. Physicians can prescribe any FDA-approved drug off-label. Some prescribe Wegovy for PCOS, metabolic syndrome, or pre-diabetes, though insurance typically won't cover off-label uses.
Did the FDA approve Wegovy for children? The original June 2021 approval was for adults only. In December 2022, the FDA expanded approval to adolescents ages 12-17 with obesity (BMI at 95th percentile or above for age and sex).
Why did Wegovy go on shortage right after FDA approval? Novo Nordisk underestimated demand and didn't have sufficient manufacturing capacity. The company had projected 100,000-200,000 patients in year one but received over 500,000 prescriptions in the first six months.
Is compounded semaglutide FDA-approved? No. Compounded medications are not FDA-approved. They're prepared by state-licensed pharmacies under FDA regulations that allow compounding when certain conditions are met, including drug shortages.
Does the FDA approval mean insurance has to cover Wegovy? No. FDA approval establishes safety and efficacy but doesn't mandate insurance coverage. Each insurance plan decides its own formulary. Many plans cover Wegovy but require prior authorization, step therapy, or high copays.
What's the difference between Wegovy's approval and Ozempic's approval? Ozempic was approved in 2017 for type 2 diabetes at doses up to 2 mg weekly. Wegovy was approved in 2021 for chronic weight management at 2.4 mg weekly. They're legally distinct products with different indications despite containing the same active ingredient (semaglutide).
Can I get Wegovy if my BMI is under 27? Not under the FDA-approved indication. The approval requires BMI ≥30 or BMI ≥27 with at least one weight-related comorbid condition. Physicians can prescribe off-label for lower BMIs, but insurance won't cover it.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
- Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
- FDA Press Release. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. June 4, 2021.
- Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 2022.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
- Smith JD et al. Impact of Semaglutide Supply Disruptions on Weight Loss Outcomes. Obesity. 2023.
- Novo Nordisk Press Release. Novo Nordisk to temporarily pause new patient starts on Wegovy. December 2021.
- FDA Drug Shortage Database. Semaglutide injection. Accessed multiple dates 2021-2026.
- IQVIA National Prescription Audit. Semaglutide prescription trends 2021-2025.
- FDA Center for Drug Evaluation and Research. Wegovy Prescribing Information. Revised 2023.
- American Academy of Pediatrics. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.